ad5-ebov

Vaccineexperimental

Clinical trial activity

3 trials · 5 clinical orgs · 0 marketing orgs

Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0

Earliest trial started Dec 1, 2014 (NCT02326194)

Timeline

2010s

  1. Jan 1, 2014

    Earliest Phase 1 Sponsor(trial)

Indications

Mechanism of action

  • EbolavirusImmunity, active

    Ebolavirus immunity, active

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Also known as

  • ad5-ebov
  • ad5-ebov0

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT02533791Phase 1Jul 1, 2015Beijing Institute of Biotechnology, Government of China, Tianjin Cansino Biotechnology Inc
NCT02401373Phase 1Mar 1, 2015People's Liberation Army of China, Tianjin Cansino Biotechnology Inc, Zhejiang University
NCT02326194Phase 1Dec 1, 2014Beijing Institute of Biotechnology, Government of China, Tianjin Cansino Biotechnology Inc
Showing 3 of 3 trials
Page 1 / 1

Organizations

Research & Development (5)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Tianjin Cansino Biotechnology IncFor profit3012014
Beijing Institute of BiotechnologyAcademic/Hospital2012014
Government of ChinaGovernment2212014
People's Liberation Army of ChinaGovernment1012015
Zhejiang UniversityAcademic/Hospital1112015
5 organizations
Page 1 / 1